Anti-monocyte chemoattractant protein-1 gene therapy attenuates nephritis in MRL/lpr mice

Rheumatology

Volumn 43, Issue 9, 2004, Pages 1121-1128

  Shimizu, S ^a   Nakashima, H ^a   Masutani, K ^a   Inoue, Y ^a   Miyake, K ^a   Akahoshi, M ^a,b   Tanaka, Y ^a   Egashira, K ^a   Hirakata, H ^a   Otsuka, T ^a   Harada, M ^a  

^a KYUSHU UNIVERSITY   (Japan)

^b RIKEN YOKOHAMA INSTITUTE   (Japan)

Author keywords

Diffuse proliferative lupus nephritis (DPLN); Gene therapy; Monocyte chemoattractant protein 1 (MCP 1); MRL lpr mice; Systemic lupus erythematosus (SLE)

Indexed keywords

CHEMOKINE RECEPTOR CCR2; MONOCYTE CHEMOTACTIC PROTEIN 1; PROTEIN INHIBITOR;

AMINO TERMINAL SEQUENCE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE DELETION; GENE MUTATION; GENE THERAPY; HISTOPATHOLOGY; IMMUNOHISTOCHEMISTRY; LASER CAPTURE MICRODISSECTION; LIFESPAN; LUPUS ERYTHEMATOSUS NEPHRITIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; SURVIVAL RATE; UPREGULATION;

ANIMALS; ANTIBODIES, ANTINUCLEAR; CHEMOKINE CCL2; DNA; GENE THERAPY; IMMUNOGLOBULIN G; KIDNEY; LEUKOCYTES; LUNG; LUPUS NEPHRITIS; LYMPHATIC DISEASES; MICE; MICE, INBRED MRL LPR; MUSCLE, SKELETAL; MUTATION; PROTEINURIA; RECEPTORS, CHEMOKINE; SIGNAL TRANSDUCTION; SPLENOMEGALY; TRANSGENES;

EID: 4544266604     PISSN: 14620324     EISSN: None     Source Type: Journal    
DOI: 10.1093/rheumatology/keh277     Document Type: Article

References (32)

1. Kashgarian M. Lupus nephritis: Pathology, Pathogenesis, Clinical Correlations, and Prognosis, 6th edn. Philadelphia: Lippincott Williams & Wilkins, 2002.
2. Theofilopoulos AN, Dixon FJ. Murine models of systemic lupus erythematosus. Adv Immunol 1985;37:269-390.
3. Masutani K, Akahoshi M, Tsuruya K et al. Predominance of Th1 immune response in diffuse proliferative lupus nephritis. Arthritis Rheum 2001;44:2097-106.
4. Rovin BH, Phan LT. Chemotactic factors and renal inflammation. Am J Kidney Dis 1998;31:1065-84.
5. Tipping PG, Kitching AR, Holdworth SR. The Formation of Glomerular Crescents. Philadelphia: Lippincott Williams & Wilkins, 2001.
6. Valente AJ, Graves DT, Vialle-Valentin CE, Delgado R, Schwartz CJ. Purification of a monocyte chemotactic factor secreted by nonhuman primate vascular cells in culture. Biochemistry 1988;27:4162-8.
7. Carr MW, Roth SJ, Luther E, Rose SS, Springer TA. Monocyte chemoattractant protein 1 acts as a T-lymphocyte chemoattractant. Proc Natl Acad Sci USA 1994;91:3652-6.
8. Allavena P, Bianchi G, Zhou D et al. Induction of natural killer cell migration by monocyte chemotactic protein-1, -2 and -3. Eur J Immunol 1994;24:3233-6.
9. Gerard C, Rollins BJ. Chemokines and disease. Nature Immunol 2001;2:108-15.
10. Rovin BH, Rumancik M, Tan L, Dickerson J. Glomerular expression of monocyte chemoattractant protein-1 in experimental and human glomerulonephritis. Lab Invest 1994;71:536-42.
11. Wada T, Yokoyama H, Su SB et al. Monitoring urinary levels of monocyte chemotactic and activating factor reflects disease activity of lupus nephritis. Kidney Int 1996;49:761-7.
12. Harigai M, Hara M, Yoshimura T, Leonard EJ, Inoue K, Kashiwazaki S. Monocyte chemoattractant protein-1 (MCP-1) in inflammatory joint diseases and its involvement in the cytokine network of rheumatoid synovium. Clin Immunol Immunopathol 1993;69:83-91.
13. Wada T, Furuichi K, Segawa-Takaeda C et al. MIP-1alpha and MCP-1 contribute to crescents and interstitial lesions in human crescentic glomerulonephritis. Kidney Int 1999;56:995-1003.
14. Zoja C, Liu XH, Donadelli R et al. Renal expression of monocyte chemoattractant protein-1 in lupus autoimmune mice. J Am Soc Nephrol 1997;8:720-9.
15. Tesch GH, Maifert S, Schwarting A, Rollins BJ, Kelley VR. Monocyte chemoattractant protein 1-dependent leukocytic infiltrates are responsible for autoimmune disease in MRL-Fas(lpr) mice. J Exp Med 1999;190:1813-24.
16. Gong JH, Ratkay LG, Waterfield JD, Clark-Lewis I. An antagonist of monocyte chemoattractant protein 1 (MCP-1) inhibits arthritis in the MRL-lpr mouse model. J Exp Med 1997;186:131-7.
17. Ni W, Egashira K, Kitamoto S et al. New anti-monocyte chemoattractant protein-1 gene therapy attenuates atherosclerosis in apolipoprotein E-knockout mice. Circulation 2001;103:2096-101.
18. Usui M, Egashira K, Ohtani K et al. Anti-monocyte chemoattractant protein-1 gene therapy inhibits restenotic changes (neointimal hyperplasia) after balloon injury in rats and monkeys. FASEB J 2002;16: 1838-40.
19. Zhang YJ, Rutledge BJ, Rollins BJ. Structure/activity analysis of human monocyte chemoattractant protein-1 (MCP-1) by mutagenesis. Identification of a mutated protein that inhibits MCP-1-mediated monocyte chemotaxis. J Biol Chem 1994;269:15918-24.
20. Zhang Y, Rollins BJ. A dominant negative inhibitor indicates that monocyte chemoattractant protein 1 functions as a dimer. Mol Cell Biol 1995;15:4851-5.
21. Yoshimura T, Yuhki N, Moore SK, Appella E, Lerman MI, Leonard EJ. Human monocyte chemoattractant protein-1 (MCP-1). Full-length cDNA cloning, expression in mitogen-stimulated blood mononuclear leukocytes, and sequence similarity to mouse competence gene JE. FEBS Lett 1989;244:487-93.
22. Yoshimura T, Yuhki N. Neutrophil attractant/activation protein-1 and monocyte chemoattractant protein-1 in rabbit. cDNA cloning and their expression in spleen cells. J Immunol 1991;146:3483-8.
23. Yoshimura T, Takeya M, Takahashi K. Molecular cloning of rat monocyte chemoattractant protein-1 (MCP-1) and its expression in rat spleen cells and tumor cell lines. Biochem Biophys Res Commun 1991;174:504-9.
24. Yoshimura T. cDNA cloning of guinea pig monocyte chemoattractant protein-1 and expression of the recombinant protein. J Immunol 1993;150:5025-32.
25. Ernst CA, Zhang YJ, Hancock PR, Rutledge BJ, Corless CL, Rollins BJ. Biochemical and biologic characterization of murine monocyte chemoattractant protein-1. Identification of two functional domains. J Immunol 1994;152:3541-9.
26. Egashira K. Molecular mechanisms mediating inflammation in vascular disease: special reference to monocyte chemoattractant protein-1. Hypertension 2003;41:834-41.
27. Burlingame RW, Rubin RL, Balderas RS, Theofilopoulos AN. Genesis and evolution of antichromatin autoantibodies in murine lupus implicates T-dependent immunization with self antigen. J Clin Invest 1993;91:1687-96.
28. Sgroi DC, Teng S, Robinson G, LeVangie R, Hudson JR Jr, Elkahloun AG. In vivo gene expression profile analysis of human breast cancer progression. Cancer Res 1999;59:5656-61.
29. Hasegawa H, Kohno M, Sasaki M et al. Antagonist of monocyte chemoattractant protein 1 ameliorates the initiation and progression of lupus nephritis and renal vasculitis in MRL/lpr mice. Arthritis Rheum 2003;48:2555-66.
30. Egashira K, Koyanagi M, Kitamoto S et al. Anti-monocyte chemoattractant protein-1 gene therapy inhibits vascular remodeling in rats: blockade of MCP-1 activity after intramuscular transfer of a mutant gene inhibits vascular remodeling induced by chronic blockade of NO synthesis. FASEB J 2000;14:1974-8.
31. Furuichi K, Wada T, Iwata Y et al. Gene therapy expressing aminoterminal truncated monocyte chemoattractant protein-1 prevents renal ischemia-reperfusion injury. J Am Soc Nephrol 2003;14:1066-71.
32. Mir LM, Bureau MF, Gehl J et al. High-efficiency gene transfer into skeletal muscle mediated by electric pulses. Proc Natl Acad Sci USA 1999;96:4262-7.